Comparable order intake growth 8%
Group sales amounted to EUR 4.3 billion, reflecting 3% increase in comparable sales
Income from operations was EUR 330 million
Adjusted EBITA margin increased by 50 basis points to 12.3% of sales
Operating cash flow of EUR 327 million, with a free cash flow of EUR 172 million
Philips reiterates full-year 2025 outlook, with margin now expected at the upper end of the range
Roy Jakobs, CEO of Royal Philips:"In this quarter we maintained our momentum, with AI-powered innovations and long-term partnerships making a real difference for patients and consumers. We drove strong order intake and accelerated sales growth, with sustained strength in North America. We expanded margin through innovation, focused execution and cost discipline, remaining firmly on-track as we navigate an uncertain macro environment including tariffs.We are taking disciplined action to achieve the highest standards in patient safety and quality, which remains our number one priority.Following our landmark agreement with Indonesia's Ministry of Health, the first Azurion system is being installed this week in East Java. This milestone marks the start of expanded access to advanced, minimally invasive care across Indonesia and demonstrates progress on our fundamentals, including supply chain agility and simplification.Our passionate team remains fully focused on driving performance and sustaining momentum through the end of the year."Group and segment performanceComparable order intake grew 8% in the third quarter, supported by continued strong performance in North America. Comparable sales grew 3.3% with growth in all segments. Margin expansion was driven by increased sales, favorable mix effects and productivity that more than offset the impact of increased tariffs. Free cash flow increased to EUR 172 million.Diagnosis & Treatment comparable sales grew 1.3%. Adjusted EBITA margin was 11.8%, down 80 bps, mainly due to tariffs and partly offset by gross margin from recently launched innovations and productivity.Connected Care comparable sales grew 5.1%. Adjusted EBITA margin improved 410 bps to 11.4%, driven by increased sales and productivity, partly offset by tariffs. Adjusted EBITA includes a non-recurring gain related to a minority investment.Personal Health comparable sales grew 10.9%. Adjusted EBITA margin increased 60 bps to 17.1%, driven by increased sales and productivity, partly offset by tariffs.Innovation highlights
Philips launched Lumea IPL in the US, bringing the world's No. 1 Intense Pulsed Light hair removal brand to the market. The launch has seen an encouraging start with strong consumer interest.
Philips unveiled radiation therapy (RT) breakthroughs, including the advanced Rembra RT and Areta RT CT scanners, delivering clearer and more consistent images, supported by the launch of helium-free BlueSeal RT MR in North America.
Philips launched Transcend Plus, the next generation EPIQ CVx and Affiniti CVx cardiovascular ultrasound systems, including 26 FDA-cleared cardiovascular ultrasound AI applications, the most in the industry.
Philips signed long-term Enterprise Monitoring as a Service (EMaaS) partnerships ...
